Add on Dapagliflozin to Insulin Pump Superior to add on Metformin for Glycemic Control in Diabetes: Study
Researchers have found in a new study that dapagliflozin combined with intensive insulin pump therapy provides better glycemic control than metformin in patients with type 2 diabetes, indicating a more effective treatment strategy for clinical practice. The study was published in the Journal of Diabetes Research by Miaoguan P. and colleagues.
In the present study, a total of 110 subjects suffering from severe hyperglycemia at the time of their diagnosis were included in the trial. The inclusion criteria of the study required participants to have an HbA1c level greater than 9%, a blood glucose level above 11.1 mmol/L, or obvious symptoms of hyperglycemia. Recently diagnosed was described as being diagnosed within the year of the start of the experiment, and all patients involved in the study were treatment-naïve or had been on treatment for less than two weeks. Of the total number of subjects, 81 participants (73.6%) gave complete information for analysis purposes. The subjects were divided into three different groups for treatment:
Group 1: Insulin pump therapy only had 25 subjects,
Group 2: Insulin, along with Dapagliflozin, had 20 subjects, and
Group 3: Insulin, along with Metformin, had 36 subjects.
Key findings:
The authors primarily concentrated on three clinical outcomes: time taken to achieve glycaemic control targets, total dose of insulin at the end of the intensive period, and its overall effects on the functioning of the pancreas.
The key finding was associated with fluctuations in fasting insulin in all groups throughout the experiment period. It was found that the greatest decrease in fasting insulin was noted in the insulin pump therapy alone and insulin pump therapy with Dapagliflozin groups.
At the same time, the insulin pump therapy with the Metformin group registered a smaller decrease.
By evaluating the selected parameters, it was established that the use of the Dapagliflozin drug facilitated a more effective physiological shift during the intensive period compared with the conventional Metformin treatment.
Conclusively, this experimental research clearly highlights an important revolution within the clinical practices regarding intensive glucose control strategies. The addition of Dapagliflozin treatment to the insulin pump therapy is considered a much more appropriate strategy compared to the combination of Metformin to achieve glycemic goals and insulin levels.
This research can be seen as a great opportunity for clinicians who deal with patients suffering from newly diagnosed T2DM in order to intensify their treatment more efficiently.
Reference:
Peng, Miaoguan, Xie, Yijuan, Liang, Naifeng, Wen, Shiyun, Zhai, Yaojie, Xie, Yingjun, Chen, Yuyi, The Impact of Different Oral Antidiabetic Drugs on Insulin Pump Intensive Therapy in Type 2 Diabetes Patients: A Clinical Study, Journal of Diabetes Research, 2026, 9957473, 8 pages, 2026. https://doi.org/10.1155/jdr/9957473
